Negative Prognostic Impact of Smoking on Long-term Survival in Patients With Nasopharyngeal Carcinoma Treated With Curative (Chemo)radiotherapy

In Vivo. 2023 Jul-Aug;37(4):1775-1785. doi: 10.21873/invivo.13266.

Abstract

Background/aim: To evaluate the effectiveness of curative (chemo)radiotherapy in patients with nasopharyngeal carcinoma and to identify prognostic factors influencing treatment outcomes.

Patients and methods: We conducted a retrospective study of 73 consecutive patients, treated with definitive (chemo)radiotherapy from 2002 to 2019 (median stage III/IV 78%). The median total dose of radiotherapy achieved was 70 Gy. Concomitant chemotherapy was given to 82% of patients.

Results: The five- and ten-year locoregional controls were 73% and 72%, respectively; the five- and ten-year distant controls were 93% and 93%, respectively. The five- and ten-year overall survival rates were 46% and 34%, respectively. A multivariate analysis identified age, smoking, and the initial response to treatment as the strongest prognostic factors in predicting survival.

Conclusion: Smoking ≤5 years before starting curative (chemo)radiotherapy for nasopharyngeal carcinoma was shown to be an independent negative prognostic factor for overall survival with a four-fold higher risk of death compared to non-smokers.

Keywords: Nasopharyngeal carcinoma; chemoradiotherapy; curative radiotherapy; prognostic factors; smoking.

MeSH terms

  • Chemoradiotherapy
  • Humans
  • Nasopharyngeal Carcinoma / therapy
  • Nasopharyngeal Neoplasms* / drug therapy
  • Nasopharyngeal Neoplasms* / pathology
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Smoking / adverse effects
  • Treatment Outcome